Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvaniti, Pinelopi, Giannoulis, George, Gabeta, Stella, Zachou, Kalliopi, Koukoulis, George K., Dalekos, George N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340979/
https://www.ncbi.nlm.nih.gov/pubmed/32671332
http://dx.doi.org/10.1016/j.jhepr.2020.100123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340979/
https://www.ncbi.nlm.nih.gov/pubmed/32671332
http://dx.doi.org/10.1016/j.jhepr.2020.100123

Ejemplares similares